Edwards Lifesciences Investors Alerted of Class Action Lawsuit for Losses
for fiscal 2024 and announced disappointing financial results for TAVR in fiscal 2Q 24. This news caused a significant 31% decline in the price of Edwards stock, from $86.95 per share on July 24, 2024, to $59.70 per share on July 25, 2024.
Investors who suffered losses are now being notified of a class-action lawsuit against Edwards Lifesciences Corporation and some of its senior executives for potential violations of federal securities laws. If you’re one of these investors, you’re encouraged to gather more information by visiting the Bleichmar Fonti & Auld LLP website. You have until December 13, 2024, to request to lead the case. The lawsuit claims violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of Edwards Lifesciences investors.
The lawsuit alleges that Edwards Lifesciences, an international company focusing on heart valve repair and replacement therapies, misrepresented the demand for its TAVR platform and its ability to meet that demand through patient activation activities. In reality, the growth of TAVR had stalled as the company’s patient activation efforts fell short, and healthcare organizations chose other treatments over TAVR. The subsequent guidance reduction for TAVR in fiscal 2024 led to a significant drop in the company’s stock price.
As an investor in Edwards Lifesciences, you may have legal options. To learn more and potentially participate in the lawsuit, you can submit your information to Bleichmar Fonti & Auld LLP. The firm operates on a contingency fee basis, meaning there is no cost to you. By visiting their website or contacting them directly, you can take steps to protect your investment.
